ReviewTherapeutic delivery2025
The role of excipients in lipid nanoparticle metabolism: implications for enhanced therapeutic effect.
Review in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid nanoparticles as active biointerfaces: From membrane interaction to systemic dysregulation.Acta pharmaceutica Sinica. B · 2026Review
- Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNPs) are multicomponent delivery vehicles for nucleic acids that are generally comprised of ionizable lipids, phospholipids, cholesterol and lipid-poly(ethylene glycol) molecules. It is well established that both the composition and relative amounts of each component significantly impact the efficiency of nucleic acid delivery by LNPs, as well as their organ-specific targeting. However, the post-delivery fate of every component is less discussed such as the degradation, clearance, and retention in the body. The longevity and metabolites of each component can greatly influence overall tolerability and safety. For instance, slowly degrading ionizable lipids, which comprise around 50% of the LNP, have been shown to illicit an extended inflammatory response. In this review significant importance is placed on chemistries that improve the tolerability and safety of certain LNP components, such as molecular modifications to ionizable lipids, lipid-poly(ethylene glycol) and nucleic acids. Additionally, we discuss how formulation strategies, such as the amount of cholesterol and phospholipids added to optimize clearance, can enhance biodegradability and reduce inflammation. Furthermore, this review will provide an understanding of the considerations around designing LNP components for better or more predictable metabolism such modified nucleic acids and biodegradable chemical linkers in ionizable lipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.